Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
[HTML][HTML] Noncoding RNA therapeutics—Challenges and potential solutions
M Winkle, SM El-Daly, M Fabbri, GA Calin - Nature reviews Drug …, 2021 - nature.com
Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and
long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of …
long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of …
[HTML][HTML] Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
[HTML][HTML] Regulation of PD-L1 expression in the tumor microenvironment
M Yi, M Niu, L Xu, S Luo, K Wu - Journal of hematology & oncology, 2021 - Springer
Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …
[HTML][HTML] Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Background In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the
recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR …
recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR …
Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond
L Ai, A Xu, J Xu - Regulation of Cancer Immune Checkpoints: Molecular …, 2020 - Springer
Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …
[PDF][PDF] Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
[HTML][HTML] PD-L1 distribution and perspective for cancer immunotherapy—blockade, knockdown, or inhibition
Cancer immunotherapy involves blocking the interactions between the PD-1/PD-L1 immune
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …
checkpoints with antibodies. This has shown unprecedented positive outcomes in clinics …
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
R Rupaimoole, FJ Slack - Nature reviews Drug discovery, 2017 - nature.com
In just over two decades since the discovery of the first microRNA (miRNA), the field of
miRNA biology has expanded considerably. Insights into the roles of miRNAs in …
miRNA biology has expanded considerably. Insights into the roles of miRNAs in …